Impact of Suspended Enzalutamide Monotherapy on Metastasis-Free Survival Among Patients With High-Risk Biochemically Recurrent Prostate Cancer
At the 2024 ASCO Gastrointestinal Cancers Symposium, Neal D. Shore, MD, Carolina Urologic Research Center, Myrtle Beach, South Carolina, presented results from the phase 3 EMBARK trial. In this trial, both enzalutamide plus leuprolide acetate and enzalutamide alone were found to be statistically superior and clinically meaningful improvement to metastasis-free survival compared with placebo plus leuprolide among patients with high-risk biochemically recurrent prostate cancer.
For patients who had sufficient PSA response in the enzalutamide and leuprolide arms, treatment was suspended at week 37. Dr Shore reported on outcomes of patients in the enzalutamide alone arm vs the leuprolide alone arm by treatment suspension status.
Source:
Shore ND, Sieber PR, Gleave M, et al. Outcomes of men with high-risk biochemically recurrent prostate cancer who suspended enzalutamide monotherapy treatment in the phase 3 EMBARK study. Presented at the 2024 ASCO Genitourinary Cancers Symposium; January 25-27, 2024; San Francisco, California. Abstract 15